1. Homepage
  2. Equities
  3. Denmark
  4. Nasdaq Copenhagen
  5. Genmab A/S
  6. Summary
    GMAB   DK0010272202

GENMAB A/S

(GMAB)
  Report
Real-time Estimate Cboe Europe  -  10:59 2022-08-10 am EDT
2583.00 DKK   +0.51%
11:21aGenmab Affirms Upgraded FY22 Guidance Amid Higher Sales of Cancer Drug Darzalex
MT
11:02aGenmab Announces Financial Results for the First Half of 2022
GL
08/09Genmab A/S - Transactions in connection with share buy-back program
AQ
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq Copenhagen
08/04/2022 08/05/2022 08/08/2022 08/09/2022 08/10/2022 Date
2619(c) 2557(c) 2564(c) 2570(c) 2583 Last
79 474 112 240 91 675 90 501 106 701 Volume
+1.63% -2.37% +0.27% +0.23% +0.51% Change
More quotes
Estimated financial data (e)
Sales 2022 12 278 M 1 687 M 1 687 M
Net income 2022 3 863 M 531 M 531 M
Net cash position 2022 18 768 M 2 579 M 2 579 M
P/E ratio 2022 43,8x
Yield 2022 -
Sales 2023 15 254 M 2 096 M 2 096 M
Net income 2023 5 182 M 712 M 712 M
Net cash position 2023 22 671 M 3 115 M 3 115 M
P/E ratio 2023 33,1x
Yield 2023 -
Capitalization 168 B 23 058 M 23 058 M
EV / Sales 2022 12,1x
EV / Sales 2023 9,52x
Nbr of Employees 1 309
Free-Float 99,6%
More Financials
Company
Genmab A/S specializes in the research and development of human and therapeutic antibodies intended for treating cancers, infectious diseases, rheumatoid arthritis, etc. Net sales break down by type of income as follows: - royalties (82.2%); - income from research and development (6.3%); - other (11.5%): primarily income from partnership agreement. At the end of 2021, the group had a portfolio of more than 20... 
Sector
Biotechnology & Medical Research
Calendar
08/10 | 11:00amEarnings Release
More about the company
Ratings of Genmab A/S
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
A-
More Ratings
All news about GENMAB A/S
11:21aGenmab Affirms Upgraded FY22 Guidance Amid Higher Sales of Cancer Drug Darzalex
MT
11:02aGenmab Announces Financial Results for the First Half of 2022
GL
08/09Genmab A/S - Transactions in connection with share buy-back program
AQ
08/08Genmab Upgrades FY22 Outlook Amid Higher Darzalex Sales
MT
08/08Genmab Raises 2022 Revenue Guidance; Shares Fall Amid Elevated Trading Volume
MT
08/08GENMAB A/S : Company Announcement - Form 6-K
PU
08/08Genmab Improves Its 2022 Financial Guidance
GL
08/08Genmab Improves Its 2022 Financial Guidance
GL
08/08Genmab A/S Revises Earnings Guidance for the Year 2022
CI
08/08Genmab and BioNTech Expand Global Strategic Collaboration to Develop and Commercialize ..
AQ
08/08GENMAB A/S : Transactions in connection with share buy-back program - Form 6-K
PU
08/08Transactions in connection with share buy-back program
GL
08/08Transactions in connection with share buy-back program
GL
08/08GENMAB A/S : Infos Business
CO
08/05RBC Cuts Price Target on Genmab to DKK3,139 From DKK3,340, Maintains Outperform Rating
MT
More news
News in other languages on GENMAB A/S
03:04aL'inflation à quitte ou double
02:44aEN DIRECT DES MARCHES : EDF, Eutelsat, Ahold Delhaize, Sika, Coinbase, Alcon, Vestas, Tesl..
02:42aAVIS D'ANALYSTES DU JOUR : Aperam, Evotec, Hugo Boss, Lonza, Prysmian, Genmab, Pets at Hom..
08/08Genmab revoit à la hausse ses perspectives pour l'exercice 22 en raison de l'augmentati..
08/08Genmab revoit à la hausse ses prévisions de revenus pour 2022 ; les actions chutent dan..
More news
Analyst Recommendations on GENMAB A/S
More recommendations
Chart GENMAB A/S
Duration : Period :
Genmab A/S Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GENMAB A/S
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 24
Last Close Price 2 570,00 DKK
Average target price 2 658,77 DKK
Spread / Average Target 3,45%
EPS Revisions
Managers and Directors
Jan G. J. van de Winkel President & Chief Executive Officer
Anthony Pagano Chief Financial Officer & Executive Vice President
Deirdre P. Connelly Chairman
Tahamtan Ahmadi Chief Medical Officer & Executive Vice President
Martin Schultz Non-Independent Director
Sector and Competitors
1st jan.Capi. (M$)
GENMAB A/S-2.28%23 058
GILEAD SCIENCES, INC.-14.61%77 767
VERTEX PHARMACEUTICALS36.08%76 638
REGENERON PHARMACEUTICALS, INC.-1.48%66 513
WUXI APPTEC CO., LTD.-20.94%40 267
BIONTECH SE-39.02%38 205